RenalSense announced today that it raised $14 million to increase global commercialization efforts and advance its next-generation products.
Jerusalem-based RenalSense develops the FDA-cleared and CE-marked Clarity RMS critical care monitoring system for the early detection of changes in renal function and acute kidney injury (AKI) risk, along with treatment monitoring.
Clarity RMS has been installed across general and cardiovascular operating rooms and ICUs, as well as transplant and COVID-19 units. Future generation sensor-based products will seek to build upon Clarity RMS to provide additional diagnostic data about renal function, as well as other vital organ function, with eyes on implementation beyond the critical care setting.
Funding came in the form of a Series A round, led by BlueRed Partners Fund (Singapore), with contributions from large healthcare-focused family offices as well as existing shareholders, according to a news release.
RenalSense said it expanded its global marketing network with new distributors in Eastern Europe, Israel and most recently in Taiwan with PAHSCO, adding to existing partners Fresenius Medical Care Medline and Gloryway.
“With the recent publication of clinical data demonstrating the clinical value of the Clarity RMS in the ICU setting, we are forging ahead with validation in additional areas like cardiology and anesthesia, in parallel with developing our pipeline of sensor-based products,” RenalSense CEO Avi Kleiman said in the release. “We are excited to have new investors on board who share our vision and understand the importance of digitally monitoring real-time renal function, bringing this parameter on par with the other vital signs of hospitalized patients.”